C9orf142 inhibitors represent a class of chemical compounds that target the protein encoded by the C9orf142 gene, which is part of the broader set of genes involved in cellular homeostasis and molecular signaling. The C9orf142 gene itself encodes a protein that is believed to function in regulatory processes related to cell cycle progression, protein interaction networks, and intracellular signaling cascades. Its exact biochemical role is still under investigation, but it is thought to have involvement in modulating certain enzymatic activities and interacting with proteins essential for maintaining cellular integrity. Inhibitors of C9orf142 typically function by binding to specific active sites or domains on the protein, interfering with its normal function, and thereby perturbing the biochemical pathways in which it is involved.
Chemically, C9orf142 inhibitors are designed with molecular features that allow them to selectively interact with the target protein while minimizing off-target effects on other proteins or signaling pathways. The structural characteristics of these inhibitors, such as their hydrogen bonding capacity, hydrophobic interactions, and stereochemistry, are optimized to achieve high-affinity binding to C9orf142. Additionally, their chemical stability, solubility, and membrane permeability are crucial considerations in their design, as these properties influence their ability to reach their intended cellular targets. Researchers are interested in studying these inhibitors as tools for dissecting the biochemical pathways regulated by C9orf142, and their development is a key area of focus for understanding the molecular underpinnings of various cellular processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
A PARP inhibitor, could indirectly affect BRAT1/C9orf142 by impacting DNA repair pathways where BRCA1 is involved. | ||||||
VE 821 | 1232410-49-9 | sc-475878 | 10 mg | $360.00 | ||
Inhibits ATR kinase, potentially affecting the cellular response to DNA damage and processes involving BRAT1/C9orf142. | ||||||
ATM Kinase Inhibitor | 587871-26-9 | sc-202963 | 2 mg | $110.00 | 28 | |
Inhibits ATM kinase, possibly influencing DNA damage response pathways where BRAT1/C9orf142 is involved. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Induces DNA crosslinking and damage, potentially impacting pathways involving BRAT1/C9orf142 in DNA repair. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
An anthracycline that causes DNA damage, could indirectly affect BRAT1/C9orf142-involved repair mechanisms. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
A chemotherapy agent that affects DNA synthesis, potentially influencing BRAT1/C9orf142-related pathways. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $78.00 $260.00 | 18 | |
Induces replication stress, which could increase the demand for BRAT1/C9orf142-mediated DNA repair processes. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Disrupts microtubule dynamics, potentially affecting cell cycle processes where BRAT1/C9orf142 is involved. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
A topoisomerase I inhibitor, potentially increasing the substrate load for BRAT1/C9orf142 in DNA repair. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Inhibits topoisomerase II, indirectly affecting DNA repair pathways possibly involving BRAT1/C9orf142. | ||||||